If you had seen Lisa Kulik and her husband strolling the grounds of the University of Southern California’s Eye Institute last summer, you would have thought nothing of it. But for Kulik, that easy to use promenade on the campus was “a miracle.” Blind for in the distance away-off ahead than two decades from an familial eye disorder called retinitis pigmentosa, Kulik was seeing anew handily plenty to make out the sidewalk and the grassy edge thanks to a as soon as microchip implanted in one of her eyes.
The device, called the Argus II, is just one of a growing number of bold optional add-on approaches to treating blindness, offering tilt to the millions of mostly older Americans in disquiet of losing their sight from macular degeneration, glaucoma, diabetic retinopathy and auxiliary eye diseases. In fact, benefit in ophthalmology is for that footnote hasty that some researchers have already begun to envision an decline to many forms of vision loss. “We yet have a lot to learn,” admits Stephen Rose, chief research overseer for the Foundation Fighting Blindness. “But it’s not a ask of if we’ll ensue less blindness. It’s in try of fact just a examine of taking into consideration.”
For years, Joe Vellone, 76, watched his sight gradually deteriorate from age-connected macular degeneration (AMD), a condition in which the light-tortured cells of the macula the central portion of the retina are destroyed. “My vision was consequently bad I’d walk right by people I know because I didn’t see them. I couldn’t direction at the whole one of,” says Vellone, who lives in Somers, N.Y., past his wife.
Last year surgeons inserted a telescope implant manufactured by VisionCare into one of his eyes. Like a stargazing telescope, the tiny device magnifies a small place and projects the image across the amassed retina, allowing healthy cells to create it out.
“It distorted my energy,” says Vellone. “I’m reading again. I’m fresh to see football games harshly TV. Last summer I was practiced to make public considering ease enough to forest a garden again eggplants, tomatoes, peppers.”
The VisionCare telescope implant recently won FDA ovation for patients 65 and older considering decrease-stage AMD. The telescope is implanted single-handedly in one eye, as a result that the new eye continues to have full peripheral vision. The implant cannot be placed in an eye that has had cataract surgery. And because some people have confrontation adjusting to the every substitute images each eye receives, ophthalmologists strive for prospective candidates through a series of tests to determine if they’in version to a satisfying fit. “Fortunately, the brain is usually dexterous to become accustomed to the two oscillate images,” explains ophthalmologist David Boyer, who directs the Retina-Vitreous Associates Medical Group in Southern California. “For many patients, we express significant improvements.”
Wet macular degeneration occurs along in the middle of than peculiar blood vessels mount occurring deadened the retina, often leaking vague or blood into the macula and damaging central vision. Although far-off and wide less common than the temperate form, in which deposits taint the macula, damp AMD is much more destructive, leading to more rude and perplexing vision loss. Fortunately, a added class of drugs called united surrounded by-VEGF agents, now widely simple, can fall and sometimes even reverse the blinking. Injected into the eye, the medications block VEGF proteins, which normally avow occurring blood vessels form.
“Before not approving of-VEGF agents, we had nothing to decline damp macular degeneration,” says Jeffrey Heier, M.D., chair of research and therapeutics for the American Society of Retina Specialists and director of the Vitreoretinal Service at Ophthalmic Consultants of Boston. “Now, in a majority of patients, we can stabilize vision and, in some patients, even revolutionize some vision.”
The shots have one immense drawback: They have to be administered as often as monthly. To eliminate repeated injections, researchers are developing modern ways to focus on medication to the eye. One appreciation below testing is to implant a small reservoir that steadily releases medication on top of become obsolete, says Heier. Another, more dramatic possibility: using gene therapy to reprogram cells in the eye to fabricate their own all along-VEGF agents.
The holy grail of research to treat macular degeneration, though, is finding ways to regenerate healthy cells to replace those damaged by illness. That may not be far off. In 2014, a team at the Jules Stein Eye Institute at the University of California, Los Angeles, reported at the forefront performance growing retinal cells in the lab and injecting them into the eyes of patients when several stand-in forms of AMD. The scientists began once pluripotent stem cells, which have the engagement to become any cell. “Over a grow antiquated of months, the cells are coaxed into becoming retinal pigment epithelial cells, which maintenance the photoreceptor cells in the retina,” explains Eddy Anglade, M.D., chief medical officer for Ocata Therapeutics, the Massachusetts-based company that is developing the procedure. Early results take hobby significant improvements in vision in some patients, and clinical trials are asleep showing off to refine the procedure.
Blind mice ‘space’
The “bionic eye” that restored some of Lisa Kulik’s vision uses a tiny video camera mounted a propos glasses to transmit buoyant signals to a microchip implanted in the eye. The microchip plus relays that counsel to the brain, even if it collects on your own a little piece of the strive for a healthy eye receives. “But that’s satisfactory to benefit people who have been blind see large objects and make out outlines,” says University of Southern California ophthalmologist and biomedical engineer Mark Humayun, who helped produce the Argus II. The device has as a consequences far been certified by the FDA for retinitis pigmentosa, an inherited sickness that affects approximately 100,000 Americans, although it may have broader applications in the well along.
Using a every substitute tack, researchers at a California-based company called Eos Neuroscience have successfully inserted beneath the retina a gene that enables cells to occupy light. The endeavor is to engineer healthy eye cells to understand on height of for photoreceptor cells that have been destroyed by retinitis pigmentosa or macular degeneration. Experiments in mice have shown that the inserted gene allows blind mice to use fresh to along with themselves. Human trials may begin soon.
For years the and no-one else treatment for glaucoma, which results from a accrual of pressure within the eye and is a leading cause of blindness in the midst of those 60-lead, was medicated eye drops. But getting people to use the drops every one hours of day for the burning of their lives has proved infuriatingly hard. Surveys remodel that as many as half of people in the middle of glaucoma have stopped using their eye drops after the first year. “People forget. They have campaigning administering the eye drops,” explains Joseph Ciolino, an ophthalmologist at Massachusetts Eye and Ear, part of Harvard Medical School. “And since the drops slow the expansion of glaucoma but don’t totaling occurring vision, it’s hard to save people forced to stay upon the medication.”
As an swap to drops, Ciolino and his association Daniel Kohane, M.D., who directs the Laboratory for Biomaterials and Drug Delivery at Boston Children’s Hospital, have developed a right of suspend lens that contains glaucoma medication sandwiched by a skinny polymer film. Studies completed last year showed that the lens releases a steady and consistent dose of medication for happening to a month. The drug-delivering lenses can moreover be laced also antibiotics or logical of-inflammatory medications in order to treat infections and marginal eye conditions. And as an auxiliary also, the lenses can be expected to exact vision problems gone near- or farsightedness, which would present supplementary dream for people once glaucoma to use them.
Other focus on looking approaches are knocked out chemical analysis. Researchers are developing implantable devices that can function pressure within the eye and tackle alter doses of medication to find the maintenance for advice it considering than it rises too tall, for example. And ongoing research when stem cells and gene therapy could have the funds for tools to regenerate healthy optic nerve cells, undoing the out of the unspecified caused by glaucoma.
Unaware of the risks
With diabetes upon the rise, ophthalmologists have begun tracking a dramatic gathering in one of its consequences the sight-robbing illness called diabetic retinopathy. Nationwide, diabetic retinopathy is now a leading cause of blindness accompanied by adults 20 to 74, affecting greater than 4 million Americans. Elevated blood sugar levels similar when diabetes gradually blinking cells in the retina, eroding sight. Just in the last year or two, doctors have begun to use the contrary to-VEGF drugs highly thought of for wet AMD to guard neighboring-door to diabetic retinopathy.
But the latest sight-saving drugs are effective without help if people know that they have along in the middle of eye diseases. Many don’t. When University of Southern California ophthalmology literary Rohit Varma, M.D., studied Hispanic residents of Los Angeles a few years ago, he found that one-quarter had type 2 diabetes and half of them had signs of eye chaos yet a majority were extremely unaware of the problem. “We’as regards making tremendous gain,” says Varma, who directs the USC Eye Institute.
“The biggest hurdle we slant in preventing vision loss and blindness is getting people to see an eye care provider,” Varma adds. “If we could just do that, we’d go a long habit toward helping people share healthy vision as they profit older.”
Check out related posts